Further branching of valproate-related carboxylic acids reduces the teratogenic activity, but not the anticonvulsant effect

Chemical Research in Toxicology

Volumn 9, Issue 5, 1996, Pages 866-870

  Bojic, Ursula ^a   Elmazar, Mohamed M A ^c   Hauck, Ralf Siegbert ^d   Nau, Heinz ^b  

^a FU Berlin   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLVALERIC ACID; 2 PROPYL 4 PENTENOIC ACID; CARBOXYLIC ACID; FATTY ACID; UNCLASSIFIED DRUG; VALERIC ACID DERIVATIVE; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG POTENCY; DRUG SYNTHESIS; EMBRYOTOXICITY; EPILEPSY; EXENCEPHALY; FETUS; FETUS WEIGHT; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NEURAL TUBE DEFECT; NEUROTOXICITY; NONHUMAN; SEDATION; STRUCTURE ACTIVITY RELATION; TERATOGENICITY;

ANIMALS; ANTICONVULSANTS; CARBOXYLIC ACIDS; EMBRYO; FEMALE; FETAL GROWTH RETARDATION; MICE; NERVOUS SYSTEM DISEASES; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP; TERATOGENS; VALPROIC ACID;

EID: 0029939450     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx950216s     Document Type: Article

References (33)

1. Meunier, H., Carraz, G., Meunier, Y., Yearned, P., and Aimard, M. (1963) Propriétés pharmocodynamiques de l'acide n-dipropylacétiques. 1er memoire: propriétés antiépileptiques (Pharmacodynamic properties of n-dipropylacetic acid. 1st report: Antiepileptic properties). Therapie 18, 435-438.
2. Robert, E., and Rosa, F. (1983) Valproate and birth defects. Lancet II, 1142.
3. Kao, J., Brown, N. A., Schmidt, B., Goulding, E. H., and Fabro, S. (1981) Teratogenicity of valproic acid: In vivo and in vitro investigations. Teratog., Carcinog., Mutagen, 1, 367-382.
4. Nau, H., and Hendrickx, A. G. (1987) Valproic acid teratogenesis. ISI Atlas Sci: Pharmacol. 1, 52-56.
5. Ehlers, K., Stürje, H., Merker H.-J., and Nau, H. (1992) Valproic acid-induced spina bifida: A mouse model. Teratology 45, 145-154.
6. Nau, H. (1986) Valproic acid teratogenesis in mice after various administration and phenobarbital-pretreatment regimens: The parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam. Appl. Toxicol. 6, 662-668.
7. Nau, H., and Löscher, W. (1986) Pharmacologic evaluation of various metabolites and analogues of valproic acid: Teratogenic potencies in mice. Fundam. Appl. Toxicol. 6, 669-676.
8. Collins, M. D., Scott, W. S., Miller, S. J., Evans, D. A., and Nau, H. (1992) Murine teratology and pharmacokinetics of the enantiomers of sodium 2-ethylhexanoate. Toxicol. Appl. Pharmacol. 112, 257-265.
9. Hauck, R. S., Wegner, C., Blumtritt, P., Fuhrhop, J.-H., and Nau, H. (1990) Asymmetric synthesis and teratogenic activity of (R)-and (S)-ethylhexanoic acid, a metabolite of the plasticizer di-(2-ethylhexyl)phthalate. Life Sci. 46, 513-518.
10. Hauck, R.-S., and Nau, H. (1992) The enantiomers of the valproic acid analogue 2-n-propyl-4-pentynoic acid (4-yn-VPA): asymmetric synthesis and highly stereoselective teratogenicity. Pharm. Res. 9, 850-855.
11. Nau, H., Hauck, R.-S., and Ehlers, K. (1991) Valproic acid-induced neural tube defects in mouse and human: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69, 310-321.
12. Hauck, R.-S., Elmazar, M. M. A., Plum, C., and Nau, H. (1992) The enantioselective teratogenicity of 2-n-propyl-4-pentynoic acid (4-yn-VPA) is due to stereoselective intrinsic activity and not differences in pharmacokinetics. Toxicol. Lett. 60, 145-153.
13. Andrews, J. E., Ebron-McCoy, M., Bojic, U., Nau, H., and Kavlock, R. J.. (1995) Validation of an in vitro teratology system using chiral substances: Stereoselective teratogenicity of 4-yn-valproic acid in cultured mouse embryos. Toxicol. Appl. Pharmacol. 132, 310-316.
14. Elmazar, M. M. A., Hauck, R.-S., and Nau, H. (1993) Anticonvulsant and neurotoxic activities of twelve analogues of valproic acid. J. Pharm. Sci. 82, 1255-1258.
15. Palaty, J., and Abbott, S. (1995) Structure-activity relationships of unsaturated analogues of valproic acid. J. Med. Chem. 38, 3398-3406.
16. Nau, H., and Scott, W. J. (1986) Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323, 276-278.
17. Wegner, Ch., and Nau, H. (1992) Alteration of embryonic folate metabolism by valproic acid during organogenesis: Implications for mechanism of teratogenesis. Neurology 42 (Suppl. 5), 17-24.
18. Fisher, E., Wittfoht, W., and Nau, H. (1992) Quantitative determination of valproic acid and 14 metabolites in serum and urine by gas chromatography/mass spectrometry. Biomed. Chromatogr. 6, 24-29.
19. Still, W. C., Kahn, M., and Mitra, A. (1978) Rapid chromatographic technique for preparative separations with moderate resolution. J. Org. Chem. 43, 2923-2925.
20. Fischer, E., Holzapfel, J., and Gewinner v., H. (1912) Über optischaktive Dialkyl-essigsäuren (On optically active dialkylacetic acids). Chem. Ber. 45, 247-257.
21. Meerwein, H. (1919) Über die wechselnde Affinitätsbeanspruchung aliphatischer Radikale (Fünfte Mitteilung über Pinakolinumlagerungen) (On the changing affinities of aliphatic radicals (5th report on pinacoline rearrangement)). Liebigs Ann. Chem. 419, 121-175.
22. Tiffenau, M. (1923) Sur quelques nouveaux acides dialcoylbarbituriques disssymétriques. I. Série éthylalcoylée (On some new asymmetric dialkylbarbituric acids. I. Ethylalkyl series). Bull. Soc. Chim. Fr. 33, 183-188.
23. Cerbai, G., Turbanti, L., Teilini, N., Fabrizi, P., and Dell'Omodarme, G. (1871) Derivati acetilenici ad attivitia antispastica Nota II-Aminoesteri dell'acido propilpropargilacetico (Acetylenic derivatives with antiepileptic properties. Report II-Aminoesters of propyl-propargylacetic acids). Farmaco, Ed. Sci. 27, 217-234.
24. Moura Campos do, M., and Amaral do, L. (1965) Neighboring group participation in addition reactions. VI. Lactonization of 4-pentenoic acid by iodine. Arch. Pharm. 298, 92-100.
25. Darzens, G. (1926) Méthode de préparation de valérolactones a substituée (A method for preparation of α-substituted valerolactones). Comp.rend.hebd.séa.acad.sié. 183, 111.
26. Bolton, S. (1984) Pharmaceutical Statistics, pp 147-152, Marcel Dekker, New York and Basel.
27. Swinyard, E. A., and Woodhead, J. H. (1982) in Antiepileptic Drugs (Woodbury, D. M., Penry, J. K., and Pippenger, C. E., Eds.) 2nd ed., pp 111-126, Raven Press: New York.
28. Löscher, W., and Nau, H. (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 5, 427-435.
29. Litchfield, J. T., and Wilcoxon, F. (1949) A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 257, 20-31.
30. Pfeiffer, C. C. (1956) Optical isomerism and pharmacological action, a generalization. Science 124, 29-31.
31. Nau, H., and Siemes, H. (1992) Dissociation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as 2-en-valproate. Pharm. Weekbl., Sci. Ed. 14 (3A), 101-107.
32. Tang, W., Borel, A. G., Fujimija, T., and Abbott, F. S. (1995) Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: Hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 8, 671-682.
33. Rekker, R. F., and Mannhold, R. (1992) Calculation of Drug Lipophilicity, VCH Verlagsgesellschaft, Weinheim, New York.